Table 1.
Clinical characteristics of patients treated with subcutaneous treprostinil referred for the pump implantation and the postimplantation parameters
| Pt | Age range [yrs.] | PAH etiology | Duration of sc. therapy [months] | Dose sc. [ng/kg/min] | Dose iv. [ng/kg/min] | WHO FC before implantation | WHO FC after implantation | FU [months] | Complications |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 42 | Corrected CHD | 6 | 38,0 | 40,0 | II | II | 29 | None |
| 2 | 28 | Corrected CHD | 50 | 62,5 | 80,0 | III | III | 24 | None |
| 3 | 37 | Idiopathic PAH | 6 | 20,0 | 30,5 | III | III | 21 | Unexpected acceleration in drug delivery |
| 4 | 40 | Idiopathic PAH | 8 | 22,5 | 22,5 | II | II | 19 | Slight dislocation of pump without clinical implications |
| 5 | 68 | Connective tissue disease | 8 | 27,0 | 30,0 | II | III | 12 | Died because of lung cancer, no problems with the pump |
| 6 | 54 | Eisenmenger | 6 | 25,5 | 43,5 | III | II | 16 | None |
| 7 | 25 | Eisenmenger | 9 | 41,3 | 42,0 | III | III | 15 | None |
| 8 | 38 | Idiopathic PAH | 27 | 40,2 | 41,3 | III | III | 13 | Dislocation of the catheter, decrease in delivery rate |
| 9 | 57 | Connective tissue disease | 10 | 33,9 | 35,4 | II | II | 11 | None |
| 10 | 53 | Idiopathic PAH | 29 | 40,4 | 44,0 | II | II | 10 | None |
| 11 | 30 | Corrected CHD | 7 | 17,0 | 40,0 | III | IV | 4 | Recurrent hematoma at implantation site, decrease in delivery rate |
| 12 | 32 | Connective tissue disease | 2 | 39,0 | 46,0 | III | II | 4 | None |
PAH – pulmonary arterial hypertension, CHD – congenital heart disease, WHO FC – WHO functional class, FU – follow-up [months]